Goldman Sachs Maintains Neutral on Agios Pharmaceuticals, Raises Price Target to $32

Goldman Sachs analyst Salveen Richter maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Neutral and raises the price target from $28 to $32.